News | November 16, 2024
Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Total Income in Q2 FY25 stood at Rs. 532.18 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
The inspection conducted by EDQM at its Visakhapatnam facility
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Subscribe To Our Newsletter & Stay Updated
